EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy

Andrew J Innes iD, Chloe Hayden, Victoria Orovboni, Simone Claudiani, Fiona Fernando, Afzal Khan, David Rees, Jennifer Byrne, Paolo Gallipoli iD, Sebastian Francis, Mhairi Copland iD, Gillian Horne iD und 19 weitere

Leukemia · 2024-11 · 38 (11) · 2443-2455

DOI: 10.1038/s41375-024-02411-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, online erschienen am 17.09.2024. Verfasst von Andrew J Innes und 30 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, Faculty of Medicine, Imperial College London, London, United Kingdom. a.innes@imperial.ac.uk. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asciminib is a potent and selective inhibitor of BCR::ABL1, with potential to avoid toxicity resulting from off-target kinase inhibition. Forty-nine patients treated with asciminib under a managed access program in the UK were evaluated for toxicity and response. Intolerance, rather than resistance (65% vs. 35%), was the most common reason for cessation of the last-line of treatment but asciminib was well tolerated, with most patients (29, 59%) remaining on treatment at a median of 14 months follow-up, and only 6 (12%) stopping for intolerance. Of 44 patients assessable for response, 29 (66%) achieved a complete cytogenetic response (CCyR) or better, with poorer responses seen in those stopping their last-line of therapy for resistance. Fewer patients with a prior history of a non-T315I- BCR::ABL1 single nucleotide variant (BSNV), or a non-T315I-BSNV detectable at baseline achieved CCyR. Serial tracking of BSNV by next generation sequencing demonstrated clonal expansion of BSNV-harbouring populations, which in some settings was associated with resistance (E459K, F317L, F359I), while in others was seen in the context of ongoing response, often with intensified dosing (T315I, I502F). These data suggest that asciminib exerts selective pressure on some BSNV-harbouring populations in vivo, some of which may respond to intensified dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fusion Proteins, bcr-ablHumansFemaleMiddle AgedMaleAgedAdultProtein Kinase InhibitorsPolymorphism, Single NucleotideLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAged, 80 and overDrug Resistance, NeoplasmYoung AdultNiacinamidePyrazoles

Substanzen

asciminibFusion Proteins, bcr-ablProtein Kinase InhibitorsNiacinamidePyrazoles

Autor:innen und Institutionen

  • Centre for Haematology, Faculty of Medicine, Imperial College London, London, United Kingdom. a.innes@imperial.ac.uk.
  • Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom. a.innes@imperial.ac.uk.
  • North West London Pathology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Centre for Haematology, Faculty of Medicine, Imperial College London, London, United Kingdom.
  • Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Medical School, Faculty of Medicine, Imperial College London, London, United Kingdom.

ORCID-Profile: Andrew J Innes, Paolo Gallipoli, Mhairi Copland, Gillian Horne, Manoj Raghavan, Daniele Avenoso, Brian J P Huntly

Förderung

  • Medical Research Council

Zitieren

APA

Innes, A. J., Hayden, C., Orovboni, V., Claudiani, S., Fernando, F., Khan, A., Rees, D., Byrne, J., Gallipoli, P., Francis, S., Copland, M., Horne, G., Raghavan, M., Arnold, C., Collins, A., Cranfield, T., Cunningham, N., Danga, A., Forsyth, P., …, & Milojkovic, D. (2024). Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia, 38(11), 2443-2455. https://doi.org/10.1038/s41375-024-02411-7

Vancouver

Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, et al. Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia. 2024;38(11):2443-2455. doi:10.1038/s41375-024-02411-7

BibTeX
@article{Innes2024,
  author = {Innes, Andrew J and Hayden, Chloe and Orovboni, Victoria and Claudiani, Simone and Fernando, Fiona and Khan, Afzal and Rees, David and Byrne, Jennifer and Gallipoli, Paolo and Francis, Sebastian and Copland, Mhairi and Horne, Gillian and Raghavan, Manoj and Arnold, Claire and Collins, Angela and Cranfield, Tanya and Cunningham, Nicholas and Danga, Akila and Forsyth, Peter and Frewin, Rebecca and Garland, Paula and Hannah, Guy and Avenoso, Daniele and Hassan, Sandra and Huntly, Brian J P and Husain, Jissan and Makkuni, Sudhakaran and Rothwell, Kate and Khorashad, Jamshid and Apperley, Jane F and Milojkovic, Dragana},
  title = {Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy},
  journal = {Leukemia},
  year = {2024},
  volume = {38},
  number = {11},
  pages = {2443--2455},
  doi = {10.1038/s41375-024-02411-7}
}
Kostenlos starten →